These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29083998)

  • 1. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.
    Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S
    Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
    Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD
    J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of immunomodulators on urological imaging].
    Peisen F; Thaiss W; Tietze N; Rausch S; Amend B; Nikolaou K; Bedke J; Stenzl A; Kaufmann S
    Urologe A; 2019 Dec; 58(12):1451-1460. PubMed ID: 31705144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumors of Renal Collecting Systems, Renal Pelvis, and Ureters: Role of MR Imaging and MR Urography Versus Computed Tomography Urography.
    Zeikus E; Sura G; Hindman N; Fielding JR
    Magn Reson Imaging Clin N Am; 2019 Feb; 27(1):15-32. PubMed ID: 30466909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the utilization of imaging for upper tract urothelial carcinoma.
    Mohapatra A; Vemana G; Bhayani S; Baty J; Vetter J; Strope SA
    Urol Oncol; 2016 May; 34(5):236.e23-8. PubMed ID: 26803434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay.
    Honda Y; Nakamura Y; Teishima J; Goto K; Higaki T; Narita K; Akagi M; Terada H; Kaichi Y; Fujii S; Hayashi T; Matsubara A; Sentani K; Yasui W; Iida M; Awai K
    Int J Urol; 2019 Nov; 26(11):1024-1032. PubMed ID: 31379021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of immunotherapy in metastatic urothelial carcinoma.
    Teo MY; Iyer G
    Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and the role of imaging.
    Carter BW; Bhosale PR; Yang WT
    Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
    Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
    Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
    [No Abstract]   [Full Text] [Related]  

  • 17. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
    Flaig TW
    J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upper urinary tract urothelial carcinoma on multidetector CT: spectrum of disease.
    Ali O; Fishman EK; Sheth S
    Abdom Radiol (NY); 2019 Dec; 44(12):3874-3885. PubMed ID: 31440804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Uro-CT protocol for the diagnosis of small urothelial neoplasms of urinary tract by quantitative analysis of contrast enhancement and correlation to the histological grading].
    Capasso R; Rossi C; Russo A; D'Andrea A; La Porta M; Cesarano E; Antinolfi G; Fonio P; Brunese L
    Recenti Prog Med; 2013; 104(7-8):406-8. PubMed ID: 24042417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.